Shield Therapeutics PLC (STX) Price Target Cut to GBX 265
Shield Therapeutics PLC (LON:STX) had its price objective reduced by FinnCap from GBX 270 ($3.63) to GBX 265 ($3.56) in a research report sent to investors on Friday morning, MarketBeat.com reports. They currently have a buy rating on the stock.
A number of other analysts have also recently weighed in on the stock. Peel Hunt reaffirmed a buy rating and issued a GBX 220 ($2.96) price objective on shares of Shield Therapeutics PLC in a report on Thursday, July 6th. Liberum Capital reaffirmed a buy rating and issued a GBX 245 ($3.29) price objective on shares of Shield Therapeutics PLC in a report on Thursday, June 22nd.
Shares of Shield Therapeutics PLC (LON:STX) opened at 157.50 on Friday. Shield Therapeutics PLC has a one year low of GBX 155.00 and a one year high of GBX 177.00. The stock has a 50 day moving average of GBX 157.50 and a 200 day moving average of GBX 162.87. The stock’s market cap is GBX 183.37 million.
COPYRIGHT VIOLATION WARNING: “Shield Therapeutics PLC (STX) Price Target Cut to GBX 265” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/shield-therapeutics-plc-stx-price-target-cut-to-gbx-265/1587879.html.
About Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.